Six-month depot formulation of leuprorelin acetate in the treatment of prostate cancer

Figures & data

Table 1 Effect of depot leuprorelin on serum prostate-specific antigen (PSA) level^38,48–50

	Leuprorelin dosage
	7.5 mg	22.5 mg	30 mg	45 mg
Pretreatment
Mean PSA	32.9	86.4	13.2	39.8
% patients with PSA <4 ng/mL	25	27	24	33
End of study
Mean PSA	1.2	1.7	1.3	3.2
% patients with PSA <4 ng/mL	96	93	83	96

Table 2 Treatment-related adverse events of 6-month (45 mg), 4-month (30 mg), 3-month (22.5) mg, and 1-month (7.5 mg) depot leuprorelin^38,48–50

	Leuprorelin dose
Adverse event: Mild – Moderate – Severe (%)	45 mg	30 mg	22.5 mg	7.5 mg
Hot flashes	33–24–0	59–18–2	49–10–0	44–12–1
Injection site reaction	14–1–0	22–0–0	89–14–0	29–4–1
Fatigue	7–5–0	10–4–0	6–0–0	13–4–0
Testicular atrophy	5–2–0	4–0–0	2–0–0	4–1–0
Gynecomastia	4–0–0	2–0–0	1–0–0	1–1–0

CrawfordEDA 12-month clinical study of LA-2585 (45.0 mg): a new 6-month subcutaneous delivery system for leuprolide acetate for the treatment of prostate cancerJ Urol200617553353616406989

 PubMed Web of Science ®Google Scholar

Perez-MarrenoRA six-month, open-label study assessing a new formulation of leuprolide 7.5 mg for suppression of testosterone in patients with prostate cancerClin Ther2002241902191412501882

 PubMed Web of Science ®Google Scholar

SartorOAn eight-month clinical study of LA-2575 30.0 mg: a new 4-month, subcutaneous delivery system for leuprolide acetate in the treatment of prostate cancerUrology2003623192312893343

 PubMed Web of Science ®Google Scholar